O
OncoCyte
Focused on cancers with large patient populations and significant unmet need
About OncoCyte
Oncocyte is a precision diagnostics company dedicated to improving patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey. The company operates in the healthcare diagnostics market, focusing on innovative solutions that empower physicians with bold and advanced diagnostic tools. Oncocyte serves doctors and patients by offering a novel multivariate gene expression test to identify immune checkpoint inhibitor responders and a test to monitor kidney transplant health through the detection of donor-derived cell-free DNA. The business model revolves around developing and commercializing these diagnostic tests, generating revenue through the sale of these tests to healthcare providers and institutions. Oncocyte's laboratory, located in Nashville, TN, holds a CLIA Certificate of Accreditation from the Centers for Medicare and Medicaid Services (CMS), ensuring high standards of quality and reliability in their diagnostic services. The company aims to deliver better patient care today by focusing on tomorrow's diagnostic needs, leveraging advanced molecular biology techniques and next-generation sequencing platforms.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Nashville, United States
- Listing
- IPO 2015
- Employees
- 65
- Open positions
- None listed
- Dealroom signal
- 48.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 3 companies, latest Apr 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Feb 2025 | $29M | — | Bio-Rad Laboratories | ↗ |
| PRIVATE PLACEMENT VC✓Equity / VC | Oct 2024 | $10M | — | Bio-Rad Laboratories | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for OncoCyte is 1.8K monthly website visits, up 718.2% over the last three months. OncoCyte's team grew 6.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chronix BiomedicalSan Jose, United StatesMolecular diagnostics company developing blood tests for monitoring minimal residual disease in cancer patients
$7.3Mvaluation
Razor GenomicsBrisbane, United States
$15Mvaluation
Insight GeneticsNashville, United StatesInsight Genetics is involved in advanced diagnostics for precision cancer care and in improving the lives of cancer patients worldwide
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Bio-Rad Laboratories
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OncoCyte on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OncoCyte’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.